Clinical Trials Browser

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Recurrence, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05573035 2025-07-01

A Study to Investigate LYL845 in Adults With Solid Tumors

Phase 1 Terminated

39 enrolled

DermatologicGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Recurrence, Colorectal Neoplasms

NCT05891197 2025-07-01

START

Terminated

10 enrolled

BreastGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Recurrence, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04034446 2025-06-03

CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Phase EARLY_PHASE1 Terminated

2 enrolled

Lymphoid

Burkitt Lymphoma, Recurrence

NCT04789655 2025-05-31

Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Terminated

45 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Recurrence, Leukemia, Myeloid, Acute

NCT04735575 2025-05-28

A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma

Phase 1/2 Terminated

40 enrolled

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence, Hematologic Neoplasms

NCT04861181 2025-05-22

NIRAPK

Phase 4 Terminated

12 enrolled

Classical hematologyGynecologic

Ovarian Neoplasms, Recurrence, Thrombocytopenia

NCT05038800 2025-05-21

MK-0482-002

Phase 1 Terminated

13 enrolled 19 charts

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05972720 2025-05-15

FIRCE-1

Phase 2 Terminated

101 enrolled

Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04464798 2025-04-29

A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

Phase 1 Terminated

62 enrolled

Lymphoid

Lymphoma, Recurrence

NCT05275673 2025-04-24

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

Phase 2 Terminated

7 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Recurrence

NCT03486067 2025-04-17

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma

Phase 1 Terminated

183 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT03765541 2025-04-10

DEXAML-03

Phase 3 Terminated

73 enrolled

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT03690869 2025-04-08

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Phase 1/2 Terminated

57 enrolled 31 charts

CNS

Diffuse Intrinsic Pontine Glioma, Glioma, Recurrence, Central Nervous System Neoplasms

NCT03038230 2025-04-06

MCLA-117 in Acute Myelogenous Leukemia

Phase 1 Terminated

80 enrolled

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT04975399 2025-03-24

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 1 Terminated

26 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT03164980 2025-03-20

COMPASS

Phase 4 Terminated

89 enrolled 20 charts

Gynecologic

Ovarian Neoplasms, Recurrence

NCT04477291 2025-03-07

A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

Phase 1 Terminated

45 enrolled

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

Clinical Trials

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML

Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma

NK4AML

ZUMA-25

Entinostat Neuroendocrine (NE) Tumor

EXPAND

Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma

Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

topMIND

A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

Engineered T-Cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors

Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies

TOMMY

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

DC15-MM-01

INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

CD123 Redirected T Cells for AML in Pediatric Subjects

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550

Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

LuminICE-203

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

A Study to Investigate LYL797 in Adults With Solid Tumors

A Study to Investigate LYL845 in Adults With Solid Tumors

START

CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia

A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma

NIRAPK

MK-0482-002

FIRCE-1

A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma

DEXAML-03

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

MCLA-117 in Acute Myelogenous Leukemia

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

COMPASS

A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS